Organogenesis Holdings Inc.
ORGOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 7, 2026 | Truist Financial | Ravi Misra | $2.00(+22%) | $1.64 | TheFly |
| May 28, 2026 | UBS | $3.00(+13%) | $2.66 | TheFly | |
| May 28, 2026 | Truist Financial | Ravi Misra | $3.00(+13%) | $2.66 | StreetInsider |
| Nov 20, 2025 | BTIG | $9.00(+75%) | $5.14 | TheFly | |
| Mar 5, 2025 | Morgan Stanley | $6.00(-0%) | $6.01 | TheFly | |
| Jun 28, 2024 | Lake Street | Brooks O'Neil | $5.00(+89%) | $2.64 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Truist Securities | maintain | Hold | Aug 7, 2026 |
| BTIG | maintain | Buy | Mar 26, 2026 |
| BTIG | maintain | Buy | Feb 27, 2026 |
| BTIG | maintain | Buy | Dec 26, 2025 |
| BTIG | maintain | Buy | Dec 15, 2025 |
| BTIG | maintain | Buy | Nov 20, 2025 |
| BTIG | maintain | Buy | Sep 26, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Aug 8, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Jul 15, 2025 |
| Morgan Stanley | maintain | Equal Weight | Mar 5, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Mar 1, 2024 |
| BTIG | maintain | Buy | Dec 27, 2023 |
| Morgan Stanley | maintain | Equal Weight | Nov 14, 2023 |
| Morgan Stanley | maintain | Equal Weight | Aug 11, 2023 |
| BTIG | maintain | Buy | Aug 10, 2023 |
| BTIG | upgrade | Neutral →Buy | May 24, 2023 |
| BTIG | downgrade | Buy →Neutral | Nov 10, 2022 |
| SVB Leerink | maintain | Outperform | Nov 10, 2021 |
| Credit Suisse | maintain | Outperform | Aug 10, 2021 |
| SVB Leerink | maintain | Outperform | May 11, 2021 |
| SVB Leerink | maintain | Outperform | Mar 17, 2021 |
| SVB Leerink | maintain | Outperform | Jan 20, 2021 |
| Credit Suisse | maintain | Outperform | Jan 7, 2021 |
| SVB Leerink | maintain | Outperform | Nov 18, 2020 |
| Credit Suisse | maintain | Outperform | Nov 10, 2020 |
Earnings History
Next report: Mar 4, 2027 · EPS est. $-0.14| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.25 | $-0.17 | $45.5M | $52.1M |
| Aug 6, 2026 | $-0.71 | $-0.35 | $43.8M | $54.3M |
| May 7, 2026 | $-0.37 | $-0.29 | $36.3M | $43.3M |
| Feb 26, 2026 | $0.31 | $0.21 | $225.1M | $172.7M |
| Nov 6, 2025 | $0.18 | $0.21 | $150.9M | $172.7M |
| Aug 7, 2025 | $-0.09 | $0.07 | $101.0M | $134.1M |
| May 8, 2025 | $-0.13 | $0.04 | $86.7M | $90.8M |
| Feb 27, 2025 | $0.04 | $-0.03 | $126.7M | $109.6M |
News
Organogenesis Holdings Inc. ( ORGO ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Gary Gillheeney - President, CEO, Chair of the Board David Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Presentation Operator Welcome, ladies and gentlemen, to the Third Quarter 2026 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions] Pleas…
Organogenesis increased third quarter net product revenue 6% quarter over quarter. Management expects annual operating expense reductions of approximately $45 million.
Organogenesis NASDAQ: ORGO reported a 70% year-over-year decline in third-quarter net product revenue and lowered the upper end of its full-year revenue outlook as the skin substitute market recovered more slowly than management had anticipated.
CANTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2026.
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of previously released results from PREPARE1, a prospective, multicenter, randomized controlled trial (RCT) evaluating PuraPly®AM (PCMP) plus standard of care (SoC) compared to SoC alone in hard-to-heal diabetic foot ulcers (DFUs). The …
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that third quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, November 5th.
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
BlackRock Inc. acquired a new position in Organogenesis (NASDAQ: ORGO) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 7,249,528 shares of the company's stock, valued at approximately $17,616,000. BlackRock Inc. owned 5.63% of Organogenesis as of its most recent